HK Stock Market Move | SIHUAN PHARM (00460) rose over 6% as net profit for the first half of the year is expected to increase by no less than 217.2%. The company's medical aesthetics business has entered a rapid growth phase.

SIHUAN PHARM (00460) rose over 6%. As of the time of writing, it increased by 6.47%, priced at HKD 0.905, with a trading volume of HKD 36.9359 million. In terms of news, recently, SIHUAN PHARM announced a positive earnings forecast, expecting to achieve revenue of no less than RMB 1.14 billion for the six months ending June 30, 2026, approximately the same as the same period last year; net profit during this period is expected to be no less than RMB 210 million, marking an increase of at least 217.2% compared to the same period last year. During this time, the group's medical aesthetics sector has continued to benefit from the steady growth of its core product, LetibotulinumtoxinA (botulinum toxin), as well as the ongoing expansion of regenerative medical aesthetic products (including baby face needles and girl needles) and functional medical aesthetic products, driving revenue growth in related businesses. China Great Wall pointed out that SIHUAN PHARM has successfully established a core category layout covering five major areas: "botulinum toxin + hyaluronic acid + regenerative materials + photoelectric equipment + kinetic elements" in its medical aesthetics business. The bank believes that the companys medical aesthetics sector has entered a phase of rapid expansion, with profitability in innovative drugs and other medications, as well as generic drugs, expected to improve, indicating that the company has reached an operational turning point.